1 김효상, "입원 환자에서 발생한 중증 저나트륨혈증의 임상상 및 경과 분석; 간질환 유무에 따른 비교" 대한신장학회 27 (27): 678-687, 2008
2 Narayen G, "Vasopressin receptor antagonists and their role in clinical medicine" 16 : 183-191, 2012
3 Gheorghiade M, "Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial" 107 : 2690-2696, 2003
4 Gross P, "Treatment of severe hyponatremia: conventional and novel aspects" 12 (12): S10-S14, 2001
5 Nemerovski C, "Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review" 32 : 1015-1032, 2010
6 Schrier RW, "Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia" 355 : 2099-2112, 2006
7 Garcha AS, "Review of tolvaptan in the treatment of hyponatremia" 3 : 315-325, 2011
8 Berl T, "Oral tolvaptan is safe and effective in chronic hyponatremia" 21 : 705-712, 2010
9 Imamura T, "Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients: association between non-responders and chronic kidney disease" 77 : 397-404, 2013
10 Waikar SS, "Mortality after hospitalization with mild, moderate, and severe hyponatremia" 122 : 857-865, 2009
1 김효상, "입원 환자에서 발생한 중증 저나트륨혈증의 임상상 및 경과 분석; 간질환 유무에 따른 비교" 대한신장학회 27 (27): 678-687, 2008
2 Narayen G, "Vasopressin receptor antagonists and their role in clinical medicine" 16 : 183-191, 2012
3 Gheorghiade M, "Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial" 107 : 2690-2696, 2003
4 Gross P, "Treatment of severe hyponatremia: conventional and novel aspects" 12 (12): S10-S14, 2001
5 Nemerovski C, "Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review" 32 : 1015-1032, 2010
6 Schrier RW, "Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia" 355 : 2099-2112, 2006
7 Garcha AS, "Review of tolvaptan in the treatment of hyponatremia" 3 : 315-325, 2011
8 Berl T, "Oral tolvaptan is safe and effective in chronic hyponatremia" 21 : 705-712, 2010
9 Imamura T, "Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients: association between non-responders and chronic kidney disease" 77 : 397-404, 2013
10 Waikar SS, "Mortality after hospitalization with mild, moderate, and severe hyponatremia" 122 : 857-865, 2009
11 Klein L, "Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study" 111 : 2454-2460, 2005
12 Upadhyay A, "Incidence and prevalence of hyponatremia" 119 (119): S30-S35, 2006
13 Shoaf SE, "In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects" 51 : 761-769, 2011
14 Verbalis JG, "Hyponatremia treatment guidelines 2007: expert panel recommendations" 120 (120): S1-S21, 2007
15 Zilberberg MD, "Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients" 24 : 1601-1608, 2008
16 Verbalis JG, "Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion" 164 : 725-732, 2011
17 Konstam MA, "Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial" 297 : 1319-1331, 2007
18 Ramires FJ, "Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy" 85 : 1207-1211, 2000
19 Peri A, "Clinical review: the use of vaptans in clinical endocrinology" 98 : 1321-1332, 2013
20 Gheorghiade M, "Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial" 167 : 1998-2005, 2007